Alto Neuroscience Faces Securities Lawsuit: Investors Encouraged to Contact DJS Law Group for Possible Lead Plaintiff Appointments.

Alto Neuroscience is being sued for alleged securities law violations related to its initial public offering and statements about the effectiveness of its treatment for major depressive disorder. Shareholders who purchased shares during the class period are encouraged to contact DJS Law Group to discuss their rights. The deadline to participate is September 19, 2025.

Alto Neuroscience, Inc. (NYSE: ANRO) is facing a class action lawsuit alleging securities law violations related to its initial public offering (IPO) and statements about the effectiveness of its treatment for major depressive disorder (MDD). The lawsuit, filed by several law firms, claims that the company made false and misleading statements and failed to disclose material adverse information during its IPO and subsequent offerings.

The lawsuit, which was filed in the United States District Court Northern District of California, alleges that Alto Neuroscience overstated the effectiveness of its drug ALTO-100 in treating MDD. According to the complaint, the company led investors to believe that ALTO-100 was more effective than it actually was, thereby overstating its clinical, regulatory, and commercial prospects. The lawsuit also claims that Alto's business and financial prospects were overstated as a result.

Investors who purchased Alto shares between February 2, 2024, and October 22, 2024, are encouraged to contact the law firms involved to discuss their legal rights. The deadline to apply to the court to be appointed lead plaintiff in the lawsuit is September 19, 2025.

The Schall Law Firm [1], Holzer & Holzer, LLC [2], and Bragar Eagel & Squire, P.C. [3] are among the firms representing investors in this case. Each firm has a toll-free number and website for investors to contact them.

Alto's stock price fell significantly on October 23, 2024, after the company announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial evaluating its effectiveness in treating MDD. This news led to a $10.17 per share decrease, a 69.99% drop.

Investors are advised to review the specific allegations and legal documents related to the lawsuit for a better understanding of the claims against Alto Neuroscience. The firms involved in the lawsuit have paid for the dissemination of this promotional communication.

References:
[1] https://www.morningstar.com/news/pr-newswire/20250902la63010/anro-investors-have-opportunity-to-lead-alto-neuroscience-inc-securities-fraud-lawsuit-with-the-schall-law-firm
[2] https://www.globenewswire.com/news-release/2025/09/02/3142989/0/en/INVESTOR-ALERT-Holzer-Holzer-LLC-Reminds-Investors-of-September-19-2025-Lead-Plaintiff-Deadline-in-the-Alto-Neuroscience-Inc-ANRO-Class-Action-Investors-With-Significant-Losses-Enc.html
[3] https://www.globenewswire.com/news-release/2025/09/03/3143576/0/en/ALTO-CLASS-ACTION-ALERT-Bragar-Eagel-Squire-P-C-Announces-that-a-Class-Action-Lawsuit-Has-Been-Filed-Against-Alto-Neuroscience-Inc-ANRO-and-Encourages-Investors-to-Contact-the-Firm.html